Three-dimensional model of the human urotensin-II receptor: Docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model

Proteins: Structure, Function and Genetics

Volumn 73, Issue 1, 2008, Pages 173-184

  Lescot, Elodie ^a   Santos, Jana Sopkova De Oliveira ^a   Colloc'h, Nathalie ^b   Rodrigo, Jordi ^a   Milazzo Segalas, Isabelle ^c   Bureau, Ronan ^a   Rault, Sylvain ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c INSA   (France)

Author keywords

Antagonists; GPCR; GPR14; Molecular modeling; Urotensin II

Indexed keywords

BENZAZEPINE DERIVATIVE; OPIATE ANTAGONIST; PALOSURAN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UROTENSIN 2 ANTAGONIST; UROTENSIN II;

ARTICLE; BINDING SITE; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINOQUINOLINES; ANIMALS; BENZAZEPINES; BINDING SITES; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; RHODOPSIN; SEQUENCE ALIGNMENT; UREA; UROTENSINS;

MAMMALIA;

EID: 50849111783     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22050     Document Type: Article

References (53)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286.
2. Maguire JJ, Kuc EK, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000;131:441-446.
3. Castel H, Diallo M, Chatenet D, Leprince J, Desrues L, Schouft MT, Fontaine M, Dubessy C, Lihrmann I, Scalbert E, Malagon M, Vaudry H, Tonon MC, Gandolfo P. Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. J Neurochem 2006;99:582-595.
4. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DLJ, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999;266:174-178.
5. Marchese A, Heiber M, Nguyen T, Heng HH, Saldivia VR, Cheng R, Murphy PM, Tsui LC, Shi X, Gregor P. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 1995;29:335-344.
6. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 2003;42:2759-2767.
7. Pearson D, Shively JE, Clark BR, Geschwind I, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 1980;77:5021-5024.
8. Conlon JM, O'Harte F, Smith DD, Tonon MC, Vaudry H. Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. Biochem Biophys Res Commun 1992;188:578-583.
9. Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 1999;457:28-32.
10. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000;10:229-237.
11. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-1274.
12. Behm DJ, Harrison SM, Ao Z, Maniscalco K, Pickering SJ, Grau EV, Woods TN, Coatney RW, Doe CP, Willette RN, Johns DG, Douglas SA. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003;139:464-472.
13. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007;20:211-217.
14. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998;95:15803-15808.
15. Chatenet D, Dubessy C, Leprince J, Boularan C, Carlier L, Segalas-Milazzo I, Guilhaudis L, Oulyadi H, Davoust D, Scalbert E, Pfeiffer B, Renard P, Tonon MC, Lihrmann I, Pacaud P, Vaudry H. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptide 2004;25:1819-1830.
16. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002;45:1799-1805.
17. Itoh H, Itoh Y, Rivier J, Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol Regul Integr Physiol 1987;252:R361-R366.
18. Kinney WA, Almond HR, Jr, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, Feinstein MA, Leung PA, Maryanoff BE. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl 2002;41:2940-2944.
19. Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 2005;19:65-75.
20. Grieco P, Carotenuto A, Campiglia P, Zampelli E, Patacchini R, Maggi CA, Novellino E, Rovero P. A new, potent urotensin II receptor peptide agonist containing a pen residue at the disulfide bridge. J Med Chem 2002;45:4391-4394.
21. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, Muller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl) -urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004;311:204-212.
22. Tarui N, Santo T, Watanabe H, Aso K, Ishihara Y; Takeda Chemical Industries, Assignee. Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives as GPR14 antagonists. WO patent 2002002530. 2002.
23. Tarui N, Santo T, Mori M, Watanabe H; Takeda Chemical Industries, Assignee. Quinoline derivatives as vasoactive agents exhibiting orphan receptor GPR14 protein antagonism. WO patent 2001066143. 2001.
24. Lescot E, Sopkova-de Oliveira Santos J, Dubessy C, Oulyadi H, Lesnard A, Vaudry H, Bureau R, Rault S. Definition of news pharmacophores for non-peptide antagonists of human urotensin-II. Comparaison with the 3D-structure of human urotensin-II and URP. J Chem Inf Mod 2007;47:602-612.
25. Lavecchia A, Cosconati S, Novellino E. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J Med Chem 2005;48:2480-2492.
26. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:733-734.
27. Boeckmann B, Bairoch A, Apweiler R, Blatter M-C, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, Pilbout S, Schneider M. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 2003;31:365-370.
28. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000;28:235-242.
29. Kelley LA, MacCallum RM, Sternberg MJ. Enhanced genome annotation using structural profiles in the program 3D-PSSM. J Mol Biol 2000;299:499-520.
30. Labesse G, Mornon J. Incremental threading optimization (TITO) to help alignment and modelling of remote homologues. Bioinformatics 1998;14:206-211.
31. Sali A, Blundell TL. Comparative protein modelling by satistaction of spatial restraints. Modeller. J Mol Biol 1993;234:779-815.
32. Sippl MJ. Recognition of errors in three-dimensional structures of proteins. Proteins 1993;17:355-362.
33. Luthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature 1992;356:83-85.
34. Douguet D, Labesse G. Easier threading through web-based comparisons and cross-validations. Bioinformatics 2001;17:752-753.
35. Faham S, Bowie JU. Bicelle crystallization: a new method for crystallizing membrane proteins yields a monomeric bacteriorhodopsin structure. J Mol Biol 2002;316:1-6.
36. Jorgensen WL, Chandrashekar J, Madura JD, Impey R, Klein ML. Refined TIP3P model for water. J Chem Phys 1983;79:926-935.
37. Brooks BR, Bruccoleri RE, Olafson BD, Sates DJ, Swaninathan S, Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983;4:187-217.
38. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher I, W E, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998;102:3586-3616.
39. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
40. Csizmadia P. Marvin sketch and Marvin view: molecule applets for the world wide web. In: Esteban Pombo-Villar RNaS-KL, editor. Switzerland MDPI; 2000. p. 367-369.
41. Smellie A, Teig SL, Towin P. Poling; promoting conformational variation. J Comput Chem 1995;16:171-187.
42. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995;245:43-53.
43. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.
44. Sybyl molecular modeling package, version 7.0, Tripos, St Louis, Mo.
45. Case DA, Darden TA, Cheatham I, Simmerling J, Wang RE, Duke R, Luo KM, Merz B, Wang DA, Pearlman M, Crowley M, Brozell S, Tsui V, Gohlke H, Mongan J, Hornak V, Cui G, Beroza P, Schafmeister C, Caldwell JW, Ross WS, Kollman PA. AMBER8. University of California, San Francisco; 2004.
46. Bissantz C, Logean A, Rognan D. High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, Three-dimensional model building, and receptor library screening. J Chem Inf Comput Sci 2004;44.
47. Knudsen MS, Tams JW, Wulff BS, Fahrenkrug J. A disulfide bond between conserved cysteines in the extracellular loops of the human VIP receptor is required for binding and activation. FEBS Lett 1997;412:141-143.
48. Heerding JN, Hines J, Fluharty SJ, Yee DK. Identification and function of disulfide bridges in the extracellular domains of the angiotensin II type 2 receptor. Biochemistry 2001;40:8369-8377.
49. Strnad J, Hadcock JR. Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem Biophys Res Commun 1995;216:913-921.
50. Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, Dixon RA. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem 1988;263:10267-10271.
51. Boivin S, Guilhaudis L, Milazzo I, Oulyadi H, Davoust D, Fournier A. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide. Biochemisty 2006;45:5993-6002.
52. Guerrini R, Camarda V, Marzola E, Arduin M, Calo G, Spagnol M, Rizzi A, Salvadori S, Regoli D. Structure-activity relationship study on human urotensin II. J Pept Sci 2005;11:85-90.
53. McGaughey GB, Gagne M, Rappe AK. pi-Stacking interactions. Alive and well in proteins. J Biol Chem 1998;25:15458-15463.